Trial Profile
A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2021
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Bronchiectasis; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections; Respiratory tract infections
- Focus Registrational; Therapeutic Use
- Acronyms CONVERT
- Sponsors Insmed
- 19 May 2021 Results of post hoc analysis assessing NNT and NNH for ALIS+GBT vs GBT alone in patients with treatment refractory Mycobacterium avium Complex Lung Disease, presented at the 117th International Conference of the American Thoracic Society.
- 19 May 2021 According to an Insmed media release, data from this trial will be presented at he virtual American Thoracic Society (ATS) 2021 International Conference.
- 19 Apr 2021 Primary endpoint has been met. (Number of Participants Achieving Durable Culture Conversion Through 3 Months Off Treatment in the LAI + MDR Arm Compared to the MDR Arm Alone)